作者
Hramiak I Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, ACCORD trial group
发表日期
2010
期刊
Lancet
卷号
376
期号
9739
页码范围
419-30
简介
Background
Hyperglycaemia is associated with increased risk of cardiovascular complications in people with type 2 diabetes. We investigated whether reduction of blood glucose concentration decreases the rate of microvascular complications in people with type 2 diabetes.
Methods
ACCORD was a parallel-group, randomised trial done in 77 clinical sites in North America. People with diabetes, high HbA1c concentrations (>7·5%), and cardiovascular disease (or ≥2 cardiovascular risk factors) were randomly assigned by central randomisation to intensive (target haemoglobin A1c [HbA1c] of <6·0%) or standard (7·0–7·9%) glycaemic therapy. In this analysis, the prespecified composite outcomes were: dialysis or renal transplantation, high serum creatinine (>291·7 μmol/L), or retinal photocoagulation or vitrectomy (first composite outcome); or peripheral neuropathy plus the first composite outcome (second composite …
引用总数
201020112012201320142015201620172018201920202021202220232024259310912913312312312616513414213713810860
学术搜索中的文章
F Ismail-Beigi, T Craven, MA Banerji, J Basile, J Calles… - The Lancet, 2010
F Ismail-Beigi, T Craven, MA Banerji, J Basile, J Calles… - DOI: https://doi. org/10.1016/S0140-6736 (10), 2016